Treatment trajectory of Sacubitril/Valsartan initiation among >50,000 older adults with heart failure with reduced ejection fraction in the United States

被引：0
|
作者：
Bhatt, A. Ankeet [1 ,2 ]
Vaduganathan, M. [3 ]
Lee, S. B. [3 ]
Desai, R. [3 ]
机构：
[1] Kaiser Permanente, San Francisco Med Ctr, San Francisco, CA USA
[2] Kaiser Permanente, Med Off, San Francisco, CA USA
[3] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA
来源：
EUROPEAN JOURNAL OF HEART FAILURE | 2023年 / 25卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：64 / 65
页数：2
相关论文
共 50 条
  • [41] THE COST-EFFECTIVENESS OF SACUBITRIL/VALSARTAN IN THE TREATMENT OF CHRONIC HEART FAILURE WITH REDUCED EJECTION FRACTION IN TURKEY
    Sarioz, F.
    Ozdemir, O.
    Direk, S.
    Caglar, P.
    Ar, I
    VALUE IN HEALTH, 2017, 20 (09) : A616 - A616
  • [42] COST-EFFECTIVENESS OF DAPAGLIFLOZIN VERSUS SACUBITRIL/VALSARTAN FOR THE TREATMENT OF HEART FAILURE WITH REDUCED EJECTION FRACTION
    McEwan, P.
    Darlington, O.
    Bergenheim, K.
    Qin, L.
    VALUE IN HEALTH, 2020, 23 : S494 - S494
  • [43] Combined treatment with sacubitril/valsartan plus dapagliflozin in patients affected by heart failure with reduced ejection fraction
    Jiang, Juan
    Gao, Jie
    Zhang, Xiuzhen
    Li, Yuanmin
    Dang, Heqin
    Liu, Yanlin
    Chen, Wenwen
    FRONTIERS IN CARDIOVASCULAR MEDICINE, 2023, 10
  • [44] Ventricular-arterial coupling and sacubitril/valsartan treatment in patients with heart failure and reduced ejection fraction
    Lavall, Daniel
    Stegmann, T.
    Parentin, L.
    Hagendorff, A.
    Schirmer, S. H.
    Laufs, U.
    EUROPEAN JOURNAL OF HEART FAILURE, 2023, 25 : 51 - 51
  • [45] Cost-effectiveness of sacubitril/valsartan for the treatment of patients with heart failure with reduced ejection fraction in Portugal
    Borges, Margarida
    Afonso-Silva, Marta
    Laires, Pedro A.
    Gouveia, Miguel
    Alarcao, Joana
    Ascencao, Raquel
    Costa, Joao
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2020, 20 (02) : 199 - 205
  • [46] Economic evaluation of sacubitril/valsartan for the treatment of chronic heart failure with reduced ejection fraction (HFrEF) in Indonesia
    Kristin, Erna
    Dwi-Endarti
    Febrinasari, Ratih Puspita
    Nugrahaningsih, Dwi Aris Agung
    Pratiwi, Woro Rukmi
    Indrajaya, Sudi
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2022, 31 : 129 - 130
  • [47] Changing the treatment of heart failure with reduced ejection fraction:clinical use of sacubitril-valsartan combination
    Edgardo Kaplinsky
    Journal of Geriatric Cardiology, 2016, 13 (11) : 914 - 923
  • [48] Budget Impact Analysis of Sacubitril/Valsartan in the Treatment of Heart Failure with Reduced Ejection Fraction (HFrEF) in Indonesia
    Kristin, Erna
    Endarti, Dwi
    Febrinasari, Ratih Puspita
    Nugrahaningsih, Dwi Aris Agung
    Pratiwi, Woro Rukmi
    INDONESIAN JOURNAL OF PHARMACY, 2022, 33 (01): : 83 - 92
  • [49] Impact of Sacubitril-Valsartan Treatment on Diastolic Function in Patients with Heart Failure and Reduced Ejection Fraction
    Pericas, Pere
    Mas-Llado, Caterina
    Ramis-Barcelo, Maria Francisca
    Valadron, Isabel
    Noris Mora, Marta
    Pasamar Marquez, Lucia
    Gonzalez Colino, Rosa
    Forteza Alberti, Jose Francisco
    Peral Disdier, Vicente
    Rossello, Xavier
    HIGH BLOOD PRESSURE & CARDIOVASCULAR PREVENTION, 2021, 28 (02) : 167 - 175
  • [50] Use of phenomapping to determine response of treatment by sacubitril/valsartan in patients with heart failure with reduced ejection fraction
    Godet, M.
    Raitiere, O.
    Chopra, H.
    Guignant, P.
    Fauvel, C.
    Gaudin, K.
    Eltchaninoff, H.
    Beuer, F.
    EUROPEAN HEART JOURNAL, 2019, 40 : 735 - 735
12345